Marijon Hélène, André Fabrice
Hôpital Saint-Antoine, service d'oncologie médicale, Paris Cedex, France.
Bull Cancer. 2011 Oct;98(9):1011-7. doi: 10.1684/bdc.2011.1379.
Fifteen percent of breast cancers overexpress Her2, a tyrosin-kinase receptor. Because of its prognosis and its incidence, several efforts have been done in the last years to better understand mechanisms of Her2 action. This led to the development of targeted therapies such as trastuzumab, monoclonal antibody directed against the Her2 extra-cellular domain. Trastuzumab provides significant clinical benefit in women with Her2-positive breast cancers. However, many women will either not respond or progress despite this treatment. The aim of this article is to summarize mechanisms of action of Her2 and of trastuzumab, and to better understand pathways activated in resistant tumors in order to identify ways to overcome them.
15%的乳腺癌过度表达Her2，一种酪氨酸激酶受体。鉴于其预后情况和发病率，在过去几年中人们开展了多项研究，以更好地了解Her2的作用机制。这促使了靶向治疗药物的研发，比如曲妥珠单抗，一种针对Her2细胞外结构域的单克隆抗体。曲妥珠单抗为Her2阳性乳腺癌女性患者带来了显著的临床获益。然而，许多女性患者即便接受了这种治疗，仍可能无反应或病情进展。本文旨在总结Her2和曲妥珠单抗的作用机制，更好地了解耐药肿瘤中激活的信号通路，从而找到克服耐药的方法。
